Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elekta ABEKTAY +3.05%72 EV-to-EBIT is 260.99 as of Aug. 17, 2026, which is 936% above its 10-year median of 25.19. GuruFocus rates EKTAY with a GF Score™ of 72/100 and a GF Value™ of $6.48 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Elekta AB ranks worse than 96.39% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Elekta AB's Enterprise Value for the quarter that ended in Apr. 2026 was $2,680 Mil.
Elekta AB's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elekta AB EV-to-EBIT Related Terms
Elekta AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Elekta AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Elekta AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elekta AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Elekta AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Elekta AB's EV-to-EBIT falls into.
Elekta AB's current Enterprise Value is $2,574 Mil.
Elekta AB's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elekta AB (EKTAY) has a EV-to-EBIT of 260.99 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Elekta AB and its competitors. This is 936% above median its historical median of 25.19. Over the past decade, Elekta AB's EV-to-EBIT has ranged from 13.42 to 265.36. According to the industry distribution chart, Elekta AB ranks #454 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 96.4%.
Is Elekta AB's EV-to-EBIT too high?
Elekta AB's current EV-to-EBIT of 260.99 is 936% above median its 10-year median of 25.19. Over the past 10 years, this metric has ranged from a low of 13.42 to a high of 265.36. The Medical Devices & Instruments industry median EV-to-EBIT is 19.29. Elekta AB's value of 260.99 is 1253% above this industry median. Based on the distribution chart, Elekta AB ranks #454 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Elekta AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elekta AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Elekta AB ranks #454 out of 471 companies for EV-to-EBIT. This places Elekta AB in the lower half of its industry. The industry median EV-to-EBIT is 19.29. Elekta AB's value of 260.99 is 1253% above this benchmark. Historically, Elekta AB's own EV-to-EBIT has ranged from 13.42 to 265.36 over the past decade. While the company's 10-year median is 25.19 vs. the industry median of 19.29, Elekta AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.29, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elekta AB's current EV-to-EBIT of 260.99 is 1253% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Elekta AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elekta AB's current EV-to-EBIT is 260.99, which is 936% above median its own 10-year median of 25.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elekta AB stock overvalued right now?
Based on GuruFocus' analysis, Elekta AB (EKTAY) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.48, compared to a current price of $5.58 — trading 13.9% below its estimated fair value. The current EV-to-EBIT is 260.99, which is 936% above median its 10-year median of 25.19 and 1253% above the Medical Devices & Instruments industry median of 19.29. Elekta AB's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Elekta AB (EKTAY), the current EV-to-EBIT is 260.99 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elekta AB (EKTAY) Overvalued in 2026?
Based on GuruFocus' analysis, Elekta AB stock appears to be undervalued.
The current stock price of $5.58 is trading 13.9% below its estimated GF Value™ of $6.48.
GuruFocus considers Elekta AB to be Modestly Undervalued.
Key valuation signals for EKTAY:
EV-to-EBIT: 260.99 (936% above median its 10-year median of 25.19)
GF Value™: $6.48 vs. price of $5.58 (13.9% below fair value)
Industry Position: 1253% above the Medical Devices & Instruments median (#454 of 471)
No single metric tells the full story. See the EKTAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
72GF Score
Get the complete analysis for EKTAY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKTAY has been successfully added to your 
